Biotech

All Articles

AstraZeneca posts information on internal competitors to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared a very early consider the performance of its in-house antibody-drug...

iTeos- GSK's TIGIT superstar presents significant renovation

.After declaring a period 3 launch based upon good midstage outcomes, iTeos and GSK are actually eve...

More collective FDA may accelerate rare illness R&ampD: document

.The FDA ought to be much more open as well as joint to release a surge in approvals of rare ailment...

Zenas, MBX, Bicara head to Nasdaq in very hot day for biotech IPOs

.It is actually an abnormally active Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bic...

Atea's COVID antiviral fails to stop hospital stays in stage 3

.Atea Pharmaceuticals' antiviral has actually neglected one more COVID-19 test, but the biotech stil...

Neurocrine's bid to save schizophrenia possibility neglects

.Neurocrine Biosciences' mental illness program pivot has actually failed. The biotech was actually ...

Sanofi pays out $110M upfront for late-stage radioligand therapy

.Sanofi has brought in an overdue access to the radioligand party, paying out 100 million europeans ...

F 2G rears $100M for second try to acquire new antifungal to market

.After F2G's first attempt to obtain a brand-new lesson of antifungal to market was actually deraile...

Moderna targets $1.1 B in R&ampD costs cuts, falls 5 systems surrounded by earnings stress

.Moderna has actually promised to cut R&ampD costs through $1.1 billion through 2027. The decision t...

Sanofi's $80M bet on Pivot dystrophy medicine finishes in stage 3 go belly up

.Merely 4 months after Sanofi bet $80 thousand in beforehand cash money on Fulcrum Therapies' losmap...